Mellon Foundation's Program Triples M.D.-Ph.D. Students' Options

While an undergraduate at Princeton University, Darren Orbach found himself faced with a dilemma. He had always envisioned being a physician, yet at Princeton he had also become fascinated by theories about the mind, which led him to an interest in investigating the workings of the brain's visual cortex. But how was he to pursue a career in basic research and be a physician, too? Like many aspiring researchers who feel a pull in the clinical direction, Orbach chose to enter a joint M.D.-Ph.D. p

Written byBruce Silver
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Typically, students accepted into an M.D.-Ph.D. program are committed from the start to one particular institution for their doctoral work. But thanks to a $1 million grant from the New York-based Andrew W. Mellon Foundation to Cornell, Orbach has a choice of three institutions, in essence tripling the advantages of an M.D.-Ph.D. program. Using the Mellon funds, Cornell teamed up with Rockefeller University and the Sloan-Kettering Institute for Cancer Research in March of this year to establish a course of study known as the Tri-institutional Medical Scientist Training Program. All three institutions are contiguously located on York Avenue on Manhattan's East Side.

The new program, which supports three M.D.-Ph.D. students a year for each of the next six years, provides not only a wide range of resources for the students, but also time for them to decide how to make the best use of those resources. Orbach and the other ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies